Peroxisome proliferator-activated receptor-alpha (PPARa) belongs to the nuclear receptor (NR) family of transcription factors and regulates lipid and glucose metabolism. Like other NRs, the regulation of gene expression by PPARa depends on cofactor recruitment to the transcription complex and multiple protein-protein interactions. In this study, Murine Double Minute 2 (MDM2), an E3 ubiquitin ligase, is identified as a PPARainteracting protein that regulates PPARa transcriptional activity. MDM2 modulated the transcriptional activity of PPARa and PPARb/d, but not PPARg in reporter assays. Knockdown of MDM2 by small interfering RNA in rat hepatoma cells inhibited ligand-induced mRNA levels of several PPARa target genes involved in lipid metabolism. MDM2 associated with PPARa on target gene promoters, and this association increased in response to Wy14,643 treatment. MDM2 interacted with PPARa and this interaction occurred with the A/B domain of PPARa. Coexpression of MDM2 increased PPARa ubiquitination and the E3 ubiquitin ligase activity of MDM2 affected PPARa protein expression and transcriptional activity. MDM2 expression was decreased in response to clofibrate in wild-type (WT), but not in PPARa null mice, indicating a PPARa-dependent regulation. These studies identify a role for MDM2 in regulating PPARamediated pathways of lipid metabolism.
Peroxisome proliferator-activated receptors (PPARs) regulate lipid and glucose metabolism, and are critical to the maintenance of cellular energy homeostasis (Desvergne et al., 2004) . In addition, they regulate several biological processes such as inflammation, differentiation, apoptosis, and wound healing (Desvergne et al., 2004) . The PPARs perform these diverse functions by acting as ligand-activated transcription factors that modulate the expression of numerous genes involved in these processes. Three different subtypes of PPARs mediate these responses; PPARa, PPARb, and PPARc. PPARa is highly expressed in tissues with high rates of fatty acid catabolism including the liver, kidney, heart, and skeletal muscle. It is activated by naturally occurring and metabolized fatty acids and by peroxisome proliferators (PPs), a diverse group of xenobiotics that include fibrate hypolidemic drugs, phthalate esters, and herbicides (Issemann and Green, 1990) . Upon long-term exposure to PPs, rodents develop hepatocellular carcinoma, and studies with PPARa null mice have shown that this subtype is responsible for the tumor-promoting activity (Hays et al., 2005; Peters et al., 1997) . Humans, however, appear to be resistant to the carcinogenic effects of fibrate drugs, and the underlying molecular mechanisms are under investigation (Cheung et al., 2004; Morimura et al., 2006; Yang et al., 2008) .
Regulation of gene expression by PPARa follows the classical ligand-dependent transcription factor mechanism. Upon ligand binding, conformational changes occur in the receptor complex that facilitates dissociation of corepressor molecules and recruitment of coactivators and coactivatorassociated proteins. Following activation, PPARa binds to PPAR-response elements (PPREs) in the promoter of target genes as a heterodimer with retinoid X receptor (RXR). The multiple protein-PPARa interactions that occur in the transcription complex are important for proper target gene regulation. Besides its heterodimeric partner RXRa, PPARa associates with heat shock proteins hsp70 and hsp90, coregulators such as PPAR binding protein, SRC-1, CBP (Tien et al., 2006) , and cAMP response element binding-binding protein/p300-interacting transactivator with ED-rich tail 2 (CITED2, also called p35srj/ mrg1/msg1) (Tien et al., 2004) .
Studies in our laboratory identified ribosomal protein L11 as a PPARa-associated protein that inhibited PPARa transcriptional activity (Gray et al., 2006) . Because ribosomal biogenesis is a crucial part of cell growth, ribosomal proteins such as L11 have recently come into focus as potential components of cell cycle control. This particular ribosomal protein interacts with MDM2, an E3 ubiquitin ligase that is well known for its degradation and negative regulation of p53 (Bhat et al., 2004; Lohrum et al., 2003; Zhang et al., 2003) . MDM2 also has p53-independent roles and interacts with several other proteins. Of importance, are MDM2-interacting proteins, Rb and E2F that play prominent roles in cell cycle regulation (Loughran and La Thangue, 2000; Martin et al., 1995; Uchida et al., 2005) .
MDM2 also ubiquitinates and regulates nuclear receptors (NRs) such as estrogen receptor (ER), glucocorticoid receptor (GR), and androgen receptor (AR) (Duong et al., 2007; Gaughan et al., 2005; Kinyamu and Archer, 2003; Lin et al., 2002; Reid et al., 2003; Sengupta and Wasylyk, 2004) . This study demonstrates that MDM2 interacts with and regulates the transcriptional activity of PPARa.
MATERIALS AND METHODS
Plasmids. MDM2 plasmids were purchased from Addgene (Cambridge, MA). The plasmid pVP16-MDM2 was generated by subcloning the coding sequence of MDM2 from pSG5-MDM2 (a kind gift from Dr Marikki Laiho at the Haartman Institute and Molecular and Cancer Biology Program, University of Helsinki, Finland). The plasmid pcdna3.1-MDM2 was kindly provided by Dr Christine Blattner (Institut für Genetik, Forschungszentrum Karlsruhe, Germany). The construction of the two-hybrid pM-PPARa constructs has been described previously (Tien et al., 2004) . The plasmid pFR-luciferase (UAS luciferase) was purchased from BD Biosciences Clontech (Palo Alto, CA), whereas pRL/TK and pRL/CMV were from Promega (Madison, WI). The PPRE reporter pACO (À581/À471) G.Luc was supplied by Dr Jonathan Tugwood (AstraZeneca Maccelsfield, UK) and has been described previously (Tien et al., 2004) . The plasmid pcDNA3.1/V5-His-PPARa has been described previously (Gray et al., 2006) . Plasmids pcDNA3.1/FLAG-PPARb and pcDNA3.1-PPARc were a kind gift from Dr Curtis Omiecinski (Department of Veterinary and Biomedical Sciences, Pennsylvania State University). MT 123-HA-ubiquitin was kindly provided by Dr Dirk Bohmann (European Molecular Biology Laboratory, Heidelberg, Germany).
In vitro interaction studies. In vitro translations were performed using the TNT-reticulocyte lysate system (Promega). The plasmid pcdna3.1-PPARa was in vitro translated in the presence of 35 S-labeled methionine, and mixed with in vitro translated pSG5-MDM2 for 2 h at 4°C in MENG buffer (25mM morpholinepropanesulfonic acid [MOPS] , 2mM ethylenediaminetetraacetic acid [EDTA], 0.02% NaN3, 10% glycerol [pH 7.5]) with 2 mg/ml bovine serum albumin, followed by immunoprecipitation with anti-MDM2 antibody (SMP14, Santa Cruz Biotechnology, Santa Cruz, CA) and protein G beads (Sigma, St Louis, MO) overnight. Following washes in MENG þ 150mM NaCl, protein complexes were eluted from the beads with 23 Tris-Glycine sample buffer, and resolved on sodium dodecyl sulfate (SDS-PAGE). PPARa was visualized by autoradiography on the dried gels.
In the Maltose binding protein (MBP)-pull down assays, PPARa (full length [FL] and domains A/B, C, D, E/F) was expressed as a MBP fusion protein and extracted from DH5a as previously described (Gray et al., 2006) . The plasmid pcdna3.1-MDM2 was in vitro translated in the presence of 35 S-labeled methionine, and incubated with equimolar amounts of the FL or different domains of PPARa-MBP in MENG containing 2 mg/ml BSA, 50lM Wy-14,643 and amylose resin for 2 h at 4°C. Following washes in MENG þ 1% NP-40 þ 150mM NaCl, protein complexes were eluted from the beads with 23 Tris-Glycine sample buffer, and resolved on SDS-PAGE. MDM2 was visualized by autoradiography on the dried gels.
Transfections and reporter assays. Lipofectamine (Invitrogen, Carlsbad, CA) was used to transfect COS-1 and 293T cells (maintained in high glucoseDulbecco's modified Eagle's medium (HG-DMEM) with 8% serum and 100 units each of penicillin and streptomycin) according to the manufacturer's instructions. For reporter assays examining transient PPRE activity, all transfections included pRL/TK (Promega) to control for transfection efficiency and ACO (Acyl-CoA oxidase)-luciferase. For reporter assays examining transient Gal4 response element activity, all transfections included pRL/CMV to control for transfection efficiency and pFR-Luciferase. Following treatment for 6 h with 0.1% dimethyl sulfoxide (DMSO) or 50lM Wy-14,643, cells were lysed and renilla and firefly luciferase activities were examined using the Dual Luciferase Assay kit (Promega).
Luciferase activity was corrected for transfection efficiency (pRLTK/pRLCMV) and extraction yield (via total protein assay).
Immunoprecipitations and Western analysis. COS-1 cells (maintained in HG-DMEM with 8% serum and 100 units each of penicillin and streptomycin) were transfected with plasmids expressing V5-PPARa, MDM2, or MDM2-C464A using Lipofectamine (Invitrogen), according to manufacturer's instructions. Following an overnight recovery, cells were treated with 0.1% DMSO or 50lM Wy-14,643 for 4 h. COS-1 cells were then lysed in RIPA buffer and cell lysates were precleared 30 min with protein G-sepharose beads (Invitrogen) at 4°C and then subjected to immunoprecipitation with anti-V5 antibody (Invitrogen) or anti-MDM2 antibody (SMP14, Santa Cruz Biotechnology) and protein G-sepharose beads overnight at 4°C. Following four washes in RIPA buffer, the bound protein complexes were eluted in 23 TrisGlycine sample buffer, and subjected to SDS/PAGE. Proteins were transferred to Immobilon-PVDF membrane (Millipore, Billerica, MA), followed by western using anti-V5 (Invitrogen) or anti-MDM2 (SMP14, Santa Cruz Biotechnology) antibodies.
Ubiquitination experiment. COS-1 cells were transfected with plasmids expressing HA-ubiquitin, V5-PPARa, MDM2, or MDM2-C464A. Following an overnight recovery, cells were treated with 5lM MG-132. Cells were lysed in RIPA buffer with protease inhibitors (Sigma) and 10lM a-iodoacetamide. The lysate was precleared for 30 min with protein G-sepharose beads at 4°C and then subjected to immunoprecipitation with anti-HA antibody (Santa Cruz) and protein G-sepharose beads overnight at 4°C. Following four washes in RIPA buffer, the bound protein complexes were eluted in 23 Tricine sample buffer, and subjected to SDS/PAGE. Proteins were transferred to Hybond-ECL-Nirocellulose membrane, followed by western using anti-V5 (Invitrogen) antibody.
siRNA and real-time PCR. FaO cells (maintained in DMEM/Nutrient F-12 Ham with 8% serum and 100 units each of penicillin and streptomycin) were transfected with MDM2 ON-TARGETplus small interfering RNA (siRNA) (catalog # J-101219-05-0010) purchased from Dharmacon (Lafayette, CO), or control ON-TARGETplus Nontargeting siRNA (Dharmacon, catalog # D-001810-02-05). Transfections were performed using Lipofectamine RNAiMax reagent (Invitrogen), according to the manufacturer's instructions. Following an overnight recovery, cells were treated with 50lM Wy-14,643 or 0.1% DMSO for 6 h. Total RNA was isolated using Tri Reagent (Sigma) according to the manufacturer's protocol. The total RNA was reverse transcribed using the ABI High Capacity cDNA Archive Kit (Applied Biosystems, Foster City, CA). Standard curves were made using serial dilutions from pooled cDNA samples. Real-time PCR was performed using the SYBR Green PCR Mater Mix (Applied Biosystems) according to the manufacturer's protocol and amplified on the ABI Prism 7300 Sequence Detection system. mRNA levels of genes measured were normalized to b-actin mRNA. Sequences for primers used are listed in Table 1 . For protein analysis, following siRNA transfection, Fao cells were lysed in RIPA buffer with protease inhibitors (Sigma). Cell lysates were subjected to SDS/PAGE and proteins were transferred to Immobilon-PVDF membrane (Millipore), followed by western blotting using anti-PPARa (Cayman Chemicals, Ann Arbor, MI) or anti-MDM2 (SMP14, Santa Cruz Biotechnology) antibodies, Visualization was performed by phophoimaging and band intensity was quantitated using Optiquant Acquisition and Analysis Software (Packard Biosciences, Meridien, CT).
Chromatin immunoprecipitations and real-time PCR. Chromatin immunoprecipitation (ChIP) was performed by modifications of the procedure by Upstate Biotechnology (Lake Placid, New York), using FaO cells grown to 95% confluence, and then treated with 0.1% DMSO or 50lM Wy-14,643 for 2 h. Briefly, chromatin was cross-linked using 1% formaldehyde for 10 min at room temperature, the cells were collected after two washings with PBS in 1 ml of lysis buffer (1% SDS, 10mM EDTA, 50mM Tris-HCl, pH 8.1), and incubated on ice for 10 min. They were then sonicated 10 times for 10 s at an output control set at 6 and duty cycle at 90% (Sonifier 250, Branson Ultrasonics, Danbury, CT), followed by centrifugation. For MDM2 ChIP or PPARa ChIP, 20 ll of supernatant was saved as input, and the rest diluted 10 times in dilution buffer (2mM EDTA, 100mM NaCl, 20mM Tris-HCl, 0.5%
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Triton-X), followed by preclearing with 40 ll of Salmon sperm DNA/Protein A agarose (Upstate) for 1 h at 4°C. Immunoprecipitation was performed overnight at 4°C with 2 lg anti-MDM2 (Santa Cruz, SMP14), anti-PPARa (Cayman, 10710, Michigan) or control antibodies. After immunoprecipitation, 60 ll of Salmon sperm DNA/Protein A agarose (Upstate) was added and the incubation continued for 3 h. Precipitates were washed sequentially for 5 min each in 1 ml of low salt wash buffer (0.1% SDS, 1% Triton-X 100, 2mM EDTA, 20mM Tris-HCl [pH 8.1], 150mM NaCl), high salt wash buffer (0.1% SDS, 1% Triton-X 100, 2mM EDTA, 20mM Tris-HCl [pH 8.1], 500mM NaCl), LiCl wash buffer (0.25M LiCl, 1% NP-40, 1% deoxycholate, 1mM EDTA, 10mM Tris-HCl [pH 8.1]), and then twice with 1 ml of Tris-EDTA buffer (1mM EDTA, 10mM Tris-HCl [pH 8.0]). Precipitated complexes were extracted from the beads through a 30-min incubation with 1% SDS, 0.1M NaHCO 3 . This step was repeated using with 15-min incubation time. For re-ChIP, 10% of the eluate from the PPARa ChIP was saved for input, and the rest diluted 40 times in dilution buffer, followed by immunoprecipitation with anti-MDM2 antibody as described above. Eluates were pooled and heated along with inputs at 65°C overnight to reverse the formaldehyde cross-linking. All buffers contained 1:100 dilution of protease-inhibitor cocktail (Sigma). DNA was purified using phenol-chloroform precipitation. Real-time PCR was performed using the SyBr Green master mix (Applied Biosystems) according to the manufacturer's protocol on the ABI Prism 7000 sequence detection system. Standard curves were made using serial dilutions from the inputs. Sequences for primers used are listed in Table 1 .
Mice. Eight to ten week old male WT, PPARa-null mice (Lee et al., 1995) on a SV129 genetic background were housed in a light (12 h light/12 h dark) and temperature (25°C) controlled environment in microisolator cages. Mice were gavaged daily with either vehicle control (corn oil) or 500 mg clofibrate/kg body weight for 14 days. Mice were euthanized, livers weighed and frozen until analysis. Livers were homogenized in lysis buffer containing 50mM Tris (pH 8), 120mM NaCl, 0.5% Nonidet P-40, and 1:100 dilution of protease-inhibitor cocktail (Sigma) after which particulates were removed by centrifugation. MDM2 in liver lysates was detected by western blotting as described above.
RESULTS

MDM2 Modulates the Ligand-Dependent Transcriptional Activity of PPARa and PPARb
The transcriptional activity of PPARa, PPARb and PPARc isotypes was examined in the presence of MDM2, by measuring the activity of a reporter gene under the control of a natural PPRE. As indicated in Fig. 1 , transfecting increasing amounts of MDM2 modulated Wy-14,643-induced PPARa activity in a dose-dependent manner. Interestingly, lower amounts of MDM2 increased reporter activity, whereas higher amounts resulted in inhibition. Transfecting increasing amounts of MDM2 inhibited GW501516-dependent PPARb reporter activity in a dose-dependent manner. No changes were seen in the absence of ligand (data not shown). PPARc activity, in the presence (Fig. 1) or absence of rosiglitazone Note. Suitable real-time PCR primers were designed using PrimerExpress (Applied Biosystems). All primers are listed 5#-3#.
FIG. 1. MDM2 modulates ligand-induced transcriptional activity of PPARa and PPARb. HEK 293T cells were transfected with plasmids expressing 4X-ACO-Luciferase, pRL/TK, MDM2, and PPARa, PPARb, or PPARc. Cells were treated with 0.1% DMSO or 50lM Wy-14,643 (PPARa), 50nM GW501516 (PPARb), or 2lM Rosiglitazone (PPARc) for 6 h, and then lysed. Luciferase activity was measured and values were corrected for transfection efficiency and protein. Values are represented after normalization to DMSO. Asterisks indicate a significant difference in ligand induction when compared with the 0 ratio group (*p < 0.05 with statistical analysis using ANOVA). The graph is representative of four independent experiments. 50 (data not shown) showed no changes upon cotransfection with MDM2.
MDM2 Regulates mRNA Levels of PPARa Target Genes
To examine the effect of MDM2 on the transcriptional activity of PPARa, siRNA was used to abrogate MDM2 expression in FaO hepatoma cells. These cells were transfected with MDM2 siRNA or control siRNA, and subsequently treated with PPARa ligand Wy-14,643. Protein levels MDM2 was reduced by 54% in the siRNA harboring cells ( Fig. 2A) and mRNA levels by 75% (Fig. 2B) . A decrease in MDM2 protein was accompanied by decreased expression of PPARa protein (Fig. 2B) . The effects of reduced MDM2 expression on endogenous PPARa target genes was measured. The genes examined were chosen based on their role in PPARa-mediated lipid metabolism, or were previously identified in gene expression microarrays in FaO cells (Tien et al., 2003) . ACO, Angiopoietin-like-protein 4 (Angptl4), enoyl CoA hydratase (ECH), and fatty acid binding protein-1 (FABP1) mRNA was increased by Wy-14,643 in control siRNA treated cells, and this induction was significantly reduced in MDM2 siRNA treated cells. Cytochrome P450 IV A1 (CYP4A1) mRNA showed a small increase in response to Wy-14,643 in control siRNA treated cells, and this induction was lost in MDM2 siRNA treated cells. In the absence of ligand, the mRNA levels of all genes examined remained unaffected by MDM2 siRNA (Fig. 2A) . No changes were seen in mRNA levels of PPARa in response to MDM2 siRNA (data not shown). These findings were further verified in MDM2/p53 null mouse embryonic fibroblasts (MEFs). Comparison of WT and MDM2/p53 null MEFs by microarray revealed several genes that were differentially regulated in response to the PPARa ligand Wy-14,643 (data not shown).
MDM2 is Present at Target Gene Promoters with PPARa
Because MDM2 associates with promoters of other NR target genes, ChIP assays were performed in FaO cells to examine if MDM2 associated with PPARa target gene promoters as a mechanism of transcriptional regulation. The association of MDM2 to PPREs was examined in the presence and absence of Wy-14,643. As shown in Figure 3A , MDM2 occupancy was detected on PPREs of ACO and Acyl-CoA Binding Protein (ACBP). When the cells were treated with Wy-14,643, an increase in MDM2 occupancy was observed. To test whether MDM2 on the PPREs is part of a PPARaassociated complex, ChIP was performed on FaO cells with an anti-PPARa antibody followed by a re-ChIP with anti-MDM2 antibody. PPARa associated with PPREs of target genes ACO and ACBP, and Wy-14,643 increased this association (Fig. 3B) . Upon re-ChIP with MDM2 (Fig. 3C) , co-association of MDM2 with PPARa was detected on ACO and ACBP PPREs, and this association increased in the presence of Wy-14,643.
No association was detected in ChIP or re-ChIP experiments with a control primer that was designed to amplify a region 10-kb upstream of the ACO promoter (data not shown).
MDM2 Associates with the A/B Domain of PPARa
To examine if the effects of MDM2 on the transcriptional activity of PPARa were due to an interaction between the two proteins, FL PPARa was in vitro translated in the presence of [ 35 S] methionine and incubated with FL in vitro translated MDM2. As shown in Figure 4A , PPARa co-immunoprecipitated with MDM2. The association occurred in the absence or presence (data not shown) of Wy-14,643. In order to identify the domain in PPARa that MDM2 interacted with, PPARa (FL and domains A/B, C, D, E/F) was expressed in bacteria as a MBP fusion. MDM2 was in vitro translated in the presence of [
35 S] methionine, incubated with PPARa-MBP, and the resultant complex was affinity purified in the presence of amylose resin. MDM2 copurified with FL and the A/B domain of PPARa. A weak interaction was also observed with the C domain of PPARa (Fig. 4B) .
To verify the interaction of MDM2 with the A/B domain of PPARa, mammalian-two-hybrid assays were performed using plasmids expressing MDM2 fused to the pVP16 activation domain, and the different domains of PPARa (A/B, C, D, E/F) and full-length (FL) PPARa in the pM vector. The Gal4 response element reporter (pFR-luciferase) was used to assess the interaction between MDM2 and PPARa. As seen in Fig. 4C , transfecting pVP16-MDM2 in HEK 293T cells resulted in increased ligand-induced reporter activity with fulllength PPARa in (top panel). The pM construct expressing different domains of PPARa was cotransfected with pVP16-MDM2 to identify the PPARa domain that was required for interaction with MDM2. An increase in reporter activity was observed with FL and pM-PPARa constructs expressing the A/ B and A-D (A/B, C, and D) domains (Fig. 4C, bottom panel) . No changes in reporter activity were seen with domains C, D, E/F, or C-F (C, D, and E/F), indicating that the A/B domain of PPARa is required for interaction with MDM2.
To further characterize the interaction, COS-1 cells were transiently transfected with plasmids expressing V5-PPARa and MDM2. Cell lysates were immunoprecipitated with anti-V5 antibody and protein complexes were detected by western blotting with anti-V5 and anti-MDM2 antibodies. As seen in Figure 5B , MDM2 co-immunoprecipitated with PPARa following overexpression.
Finally, to detect if the two proteins interacted at physiological levels of expression, FaO cell lysates were immunoprecipitated with control rat IgG, anti-PPARa or anti-MDM2 antibodies, and protein complexes detected by western blotting. As indicated in Figure 4D , PPARa co-immunoprecipitated with MDM2. No significant difference was found in the interaction between PPARa and MDM2 in the presence of Wy-14,643 (data not shown).
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The E3 Ubiquitin Ligase Activity of MDM2 Regulates PPARa Protein Expression and Transcriptional Activity
Because knockdown of MDM2 expression by siRNA resulted in decreased protein levels of PPARa ( Fig. 2A ) and no changes in PPARa mRNA were seen with MDM2 siRNA (data not shown) in FaO cells, MDM2/p53 null MEFs were used to determine if MDM2 modulated the transcriptional activity of PPARa by regulating its protein expression. (B) FaO cell lysates were resolved by SDS-PAGE and proteins were detected by western blotting with anti-MDM2 and anti-PPARa antibodies. The western is representative of three independent experiments. The graph depicts the mean band intensity (relative to glyceraldehyde 3-phosphate hydrogenase) from the three independent experiments. Quantitation of bands was performed using Optiquant Image Acquisition and Analysis software. Asterisks indicate a significant difference when compared with the corresponding control siRNA group (*p < 0.05 with statistical analysis using ANOVA).
Because MDM2 null MEFs are not available, MDM2/p53 double null MEFs were used. PPARa was detected in MEF lysates by immunoblotting with anti-PPARa antibody. MDM2/p53 null MEFs expressed lower levels of PPARa, and unlike WT MEFs, did not show an increase in response to PPARa ligand Wy-14,643 treatment. Transfecting MDM2 in MDM2/p53 null MEFs increased PPARa protein levels and restored the response to ligand (Fig. 5A) .
In order to determine if the above effects of MDM2 on PPARa protein expression was mediated by the E3 ubiquitin ligase function of MDM2, COS-1 cells were transiently transfected with plasmids expressing PPARa, MDM2 WT, or MDM2-C464A that carries a point mutation in the RING finger, disrupting its E3 ubiquitin ligase function. Following transfections, cells were treated with 0.1% DMSO or 50lM Wy-14,643 and immunoprecipitated with anti-V5 antibody, and protein complexes detected by western blotting with anti-V5 and anti-MDM2 antibodies. As shown in Figure 5B , both WT and RING finger mutant MDM2 co-immunoprecipitated with PPARa. Interestingly, in contrast to increased PPARa expression that was observed when MDM2 was expressed in MEFs (Fig. 5A) , association of PPARa with WT MDM2 in COS-1 cells resulted in decreased protein levels of PPARa. However, association with MDM2-C464A did not change protein levels of PPARa, suggesting that the E3 ubiquitin ligase function of MDM2 is required for its regulation of PPARa protein levels. When protein bands were quantitated from multiple (n ¼ 4) experiments, no significant difference was found in the interaction between PPARa and MDM2 in the presence of Wy-14,643. The MDM2-C464A mutant expressed slightly higher than MDM2 WT under these experimental conditions, and the increased levels of MDM2-C464A that coimmunoprecipitated with PPARa in comparison with MDM2 WT may be a result of the differences in expression levels. However, in spite of its higher expression levels, the MDM2-C464A mutant had no effect on PPARa protein expression (Fig. 5B) .
In order to determine if MDM2 could promote ubiquitination of PPARa, COS-1 cells were transiently transfected with plasmids expressing V5-PPARa, HA-Ubiquitin and MDM2 WT or MDM2-C464A, and treated with proteasome inhibitor MG-132. Cell lysates were immunoprecipitated with anti-HA antibody and ubiquitinated PPARa species were detected by immunoblotting with anti-V5 antibody. Increased ubiquitination of PPARa was detected in the presence of MDM2 WT, but not MDM2-C464A (Fig. 5C) .
To determine if the ubiquitin ligase function is required for MDM2-mediated modulation of PPARa-dependent transactivation, the activity of a reporter gene under the control of a natural PPRE was measured in HEK 293T cells. As indicated in Figure 6 , transfecting increasing amounts of MDM2 WT modulated ligand-mediated induction of reporter activity in a dose-dependent manner (left panel). Interestingly, lower amounts of MDM2 WT resulted in an increase, whereas higher amounts resulted in a decrease in reporter activity. However, transfecting MDM2-C464A did not result in any changes in reporter activity (right panel), suggesting that a functional E3 ubiquitin ligase domain is required for modulating PPARa transactivation. These differences were not due to different transfection efficiencies because both FIG. 3 . MDM2 associates with PPARa on target gene promoters. FaO cells were treated with 0.1% DMSO or 50 lM Wy-14,643 for 2 h and ChIP was performed with anti-PPARa alone (A), anti-MDM2 alone (B), or anti-PPARa followed by re-ChIP with anti-MDM2 (C). The extracted DNA was quantitated by real-time PCR, relative to input. *Indicates a significant increase when compared with the corresponding DMSO group. #Indicates a significant increase when compared with the corresponding control ip group (p < 0.05 with statistical analysis using ANOVA). The graphs represent mean values obtained from three independent experiments.
MDM2 REGULATES PPAR-a 53 MDM2 WT and MDM2-C464A expressed at similar levels in HEK 293T cells (data not shown).
MDM2 is Regulated In Vivo in a PPARa-Dependent Manner
Finally, the regulation of MDM2 in response to PPARa ligand was examined in vivo. Wild-type and PPARa null mice (Lee et al., 1995) were maintained on a clofibrate or control diet for 2 weeks, following which their livers were analyzed for protein levels of MDM2. A decrease in MDM2 protein expression was detected in response to clofibrate in WT, but not in PPARa null (Fig. 7) , indicating a PPARa-dependent regulation.
DISCUSSION
The ubiquitin-proteasome system has emerged as an important regulator of NR function. Both NRs and their coregulators are targeted to the ubiquitin-proteasome system for degradation. Several ubiquitin-proteasome pathway enzymes have been characterized as coactivators for NRs and ubiquitin-proteasome components are recruited to the promoters of NR regulated genes (Kinyamu et al., 2005; RochetteEgly, 2005) . This study identifies an E3 ubiquitin ligase, MDM2 that associates with and regulates the transcriptional activity of PPARa. Ligand-induced mRNA levels of PPARa target genes involved in lipid metabolism were decreased with MDM2 siRNA, indicating that MDM2 affects PPARa transcriptional activity.
To understand the mechanism behind MDM2-mediated regulation of PPARa, PPARa protein expression was examined in FaO cells transfected with MDM2 siRNA and in MDM2/p53 null MEFs. Both cells showed decreased protein levels of PPARa and MDM2/p53 null MEFs were less responsive to ligand, when compared with WT MEFs which showed a significant increase in PPARa protein in the presence of ligand. The response to ligand was restored in the null MEFs when MDM2 was transfected, suggesting that MDM2 stabilizes PPARa protein levels in response to ligand. This was in contrast to studies in COS-1 cells where MDM2 coexpression decreased PPARa protein levels. This effect required the ubiquitin ligase function of MDM2. Because the COS-1 studies used overexpressed PPARa, whereas the MEF studies examined endogenous PPARa, it is possible that MDM2 responds differently to different expression levels of PPARa. Lower expression of PPARa may provoke MDM2-mediated nonproteolytic stabilization events such as monoubiquitination and/or recruitment of coactivators, contributing to increased PPARa activity. This has been observed for MDM2-mediated regulation of the HIV-1 transactivator, Tat. MDM2 positively regulates Tat transactivation by nonproteolytic ubiquitination (Bres et al., 2003) . Higher expression of PPARa may provoke MDM2-mediated polyubiquitination and degradation as a means of controlling the transcriptional response. This could explain the decreased transcriptional activity of PPARa that was observed in PPRE-dependent reporter assays. MDM2-mediated ubiquitination of the AR destabilizes AR and attenuates AR activity (Gaughan et al., 2005) , indicating that MDM2 can act as a negative regulator of NR function.
Because increased transcriptional activity of PPARa was observed in PPRE-dependent reporter assays at lower amounts of coexpressed MDM2, another possibility is that polyubiquitination and increased turnover contribute to increased transcriptional activity. Degradation of NRs such as retinoic acid receptor (RARc2), progesterone receptor (PR) and GR is linked to transcriptional activation (Gianni et al., 2002; Shen et al., 2001; Wallace and Cidlowski, 2001) . It has been proposed that degradation by the ubiquitin-proteasome pathway might provide an efficient mechanism for regulating the cyclic interaction of NRs with the promoter (Rochette-Egly, 2005) . This is in contrast to previous reports which show that inhibition of PPARa degradation increases its transcriptional activity (Blanquart et al., 2002) . These differences may be attributed to analysis of PPARa activity at a single time point. It is likely that PPARa degradation is regulated in a timely manner to allow for accurate sensing of ligand concentrations and tighter control over transcriptional events. This has been FIG. 5 . E3 ubiquitin ligase function of MDM2 regulates PPARa protein expression. (A) Wild-type MEFs were transfected with an empty vector or plasmid expressing MDM2, following which they were treated with 0.1% DMSO or 50lM Wy-14,643 for 4 h. Cell lysates were resolved by SDS-PAGE and proteins were detected by western blotting with anti-PPARa antibody. The western is representative of three independent experiments. The graph depicts the mean band intensity from the three independent experiments. Quantitation of bands was performed using Optiquant Image Acquisition and Analysis software. Asterisks indicate a significant difference when compared with the corresponding control (no Wy-14,643 treatment) group. (*p < 0.05 with statistical analysis using ANOVA). (B) COS-1 cells were transfected with plasmids expressing V5-PPARa, MDM2, or MDM2-C464A and treated with 0.1% DMSO or 50lM Wy-14,643 for 4 h. Cell lysates were immunoprecipitated with anti-V5 antibody, protein complexes resolved by SDS-PAGE and detected by western blotting with anti-V5 or anti-MDM2 antibodies. The Western is representative of three independent experiments. (C) COS-1 cells were transfected with plasmids expressing V5-PPARa, MDM2, and HAUbiquitin, and treated with 5lM MG-132. Cell lysates were immunoprecipitated with anti-HA antibody, protein complexes resolved by SDS-PAGE and detected by Western blotting with anti-V5 antibody. The Western is representative of three independent experiments. MDM2 REGULATES PPAR-a observed with the ER, whose transcriptional activity is enhanced under the influence of MDM2, possibly by affecting the periodicity of receptor proteasomal degradation and the association of ER to target gene promoters in response to ligand concentrations (Reid et al., 2003) .
MDM2 siRNA studies indicate that MDM2 enhances Wy-14,643-induced transcriptional activity of PPARa, and ChIP experiments revealed increased occupancy of MDM2 on PPREs in the presence of Wy-14,643. In contrast to MDM2-mediated increase in PPARa activity seen in FaO cells, the protein expression of MDM2 was decreased in mice treated with Wy-14,643. This decrease was observed in WT but not in PPARa null mice, indicating a PPARa-dependent regulation of MDM2. Although these results were from experiments in different model systems (hepatoma cells and mice), it is possible that PPARa-mediated inhibition of MDM2 expression represents a feedback regulation to control activation of PPARa in the presence of ligand. The expression of MDM2 is also negatively regulated by the orphan receptor TR3 (Zhao et al., 2006) . Other NRs that regulate MDM2 expression are the ER (Hori et al., 2002) , thyroid hormone receptor (Qi et al., 1999) , and constitutive androstane receptor (CAR) (Huang et al., 2005) , indicating a broad role for MDM2 as a regulator of NR function. Although the current studies indicate an involvement for PPARa in regulation of MDM2 expression, it will be of interest to determine if PPARa is involved directly or if other cofactors are involved.
MDM2 interacted with the A/B domain of PPARa as revealed by in vitro assays and mammalian-two-hybrid assays. This domain contains the ligand-independent AF-1 transactivation function, and our laboratory has demonstrated that phosphorylation in the A/B domain by GSK3b regulates PPARa activity (unpublished results; Burns and Vanden Heuvel, 2007) .
Preliminary data indicate that a PPARa mutant defective in GSK3b-mediated phosphorylation is regulated differentially by MDM2. GSK3b is important in insulin signaling and understanding the interplay between MDM2 and GSK3b in regulating PPARa activity may be important in understanding the regulation of glucose metabolism by PPARa. A role for GSK3b in regulating MDM2 has already been demonstrated with regards to p53 stabilization (Kulikov et al., 2005) .
MDM2 plays a central role in regulating p53 stability and this pathway is critical for cellular response to aberrant oncogenic signaling. Hepatocarcinogenesis induced by PPs in rodents has been attributed to increased cell proliferation and suppression of apoptosis leading to imbalanced hepatocyte growth control (Klaunig et al., 2003) . One compelling case for the role of p53 in PP-induced cell proliferation is the increased levels of p53 in Wy-14,643-treated humanized PPARa mice, in contrast to the comparatively lower p53 expression in Wy-14,643-treated WT mice (Morimura et al., 2006) . The lack of significant increase of p53 levels in WT mice may allow cells to escape p53-mediated cell cycle surveillance, leading to hepatocellular proliferation and carcinogenesis, effects that are absent in humanized PPARa mice (Morimura et al., 2006) Interestingly, p53 and p21 protein are increased in mice administered Wy-14,643 (Ma et al., 1997) . Other studies with p53 and its target genes such as p21 following PP administration have shown varied results (Hoivik et al., 2004; Knight et al., 2005; Ma et al., 1997; Peters et al., 1997; Simbula et al., 2004) . Cell cycle regulators such as cyclins and cyclin-dependent kinases (CDKs) are increased in mice administered PPs (Hays et al., 2005; Ma et al., 1997; Rininger et al., 1996 Rininger et al., , 1997 . This study demonstrated a decrease in MDM2 protein expression in mice administered clofibrate. In addition to regulating p53, MDM2 also promotes FIG. 6 . E3 ubiquitin ligase function of MDM2 regulates transcriptional activity. HEK 293T cells were transfected with plasmids expressing 4X-ACOLuciferase, pRL/TK, V5-PPARa, MDM2 WT, or MDM2-C464A. Cells were treated with 0.1% DMSO or 50lM Wy-14,643 for 6 h, and then lysed. Luciferase activity was measured and values were corrected for transfection efficiency and protein. Asterisks indicate a significant difference in Wy-14,643 induction when compared with the 0 ratio group (*p < 0.05 with statistical analysis using ANOVA). The graph is representative of three independent experiments. 56 cell cycle progression by regulating the Rb/E2F complex (Levav-Cohen et al., 2005) . The relevance of this role in PPinduced cell proliferation is worthy of investigation. Because studies with PPARa null mice demonstrated a PPARadependent regulation of MDM2, it will be of interest to identify the mechanism of this regulation. Characterizing the role of PPARa as direct or involving other coregulators in regulating MDM2 may contribute to understanding the effects of PPs on cell cycle regulation.
The studies presented here provide a basis for examining the role of PPARa in regulating the MDM2-p53 pathway during cancer development. Additionally, these studies identify for the first time, a role for MDM2 in regulating PPARa-mediated pathways of lipid and glucose metabolism. The various biological processes regulated by PPARs are crucial in control of disorders such as diabetes, inflammation, and cardiovascular ailments. Further work on the role of MDM2 and the ubiquitinproteasome system in regulating PPARs holds promise towards the understanding and treatment of these diseases. 
